<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="HSR">
        <PMID Version="1">19999289</PMID>
        <DateCompleted>
            <Year>2009</Year>
            <Month>12</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>10</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1064-590X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>64</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2009</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Food and drug law journal</Title>
                <ISOAbbreviation>Food Drug Law J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Off-label use reimbursement.</ArticleTitle>
            <Pagination>
                <MedlinePgn>391-403</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>In this study, the authors examine factors underlying payer off-label use reimbursement policies. Updating a study published 14 years ago, presenting the results of the survey of 179 payers administering public (Medicare and Medicaid) pharmacy benefits. The focus is on payers administering pharmacy benefits in the public sector for two reasons: First, transparency; there is a tendency for such payers to reveal more about their decisionmaking processes than payers that exclusively deal with the commercial market. Second, Medicare and Medicaid set the pace in terms of specific policies on off-label use reimbursement, particularly with regard to anti-cancer agents and biologics. The authors investigate the role of primary and secondary sources governing reimbursement of unlabeled indications, including biopharmaceutical compendia, peer-reviewed literature, and clinical practice guidelines. The findings point to the continued variation of off-label use reimbursement policies across payers. Furthermore, the survey data shed light on payer efforts to design off-label use reimbursement strategies, including the use of cost-effectiveness.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cohen</LastName>
                    <ForeName>Joshua</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tufts Center for the Study of Drug Development, Tufts University, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wilson</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Faden</LastName>
                    <ForeName>Laura</ForeName>
                    <Initials>L</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Food Drug Law J</MedlineTA>
            <NlmUniqueID>9215384</NlmUniqueID>
            <ISSNLinking>1064-590X</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>T</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D014487" MajorTopicYN="N">Centers for Medicare and Medicaid Services, U.S.</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
                <QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005569" MajorTopicYN="N">Formularies as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007349" MajorTopicYN="N">Insurance, Health, Reimbursement</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
                <QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
                <QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D056687" MajorTopicYN="N">Off-Label Use</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
                <QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011358" MajorTopicYN="Y">Product Surveillance, Postmarketing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19999289</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
